Glucose Metabolic Responses to Colesevelam Alone or in Combination With Sitagliptin in Type 2 Diabetes Mellitus: A Randomized Open-Label Mechanism-of-Action Study

被引：0
|
作者：
Beysen, Carine
Turner, Scott
Deines, Kristin
Tsang, Ellen
Riiff, Tim
Protasio, Joan
Hellerstein, Marc
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
379-OR
引用
收藏
页码：A96 / A97
页数：2
相关论文
共 50 条
  • [1] Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
    Gautam, Kumar
    Tripathy, Ratikanta
    Meher, Dayanidhi
    Sahoo, Jyoti Prakash
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
  • [2] Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study
    Tsurutani, Yuya
    Nakai, Kazuki
    Inoue, Kosuke
    Azuma, Kosuke
    Mukai, Sei
    Maruyama, Seitaro
    Iizuka, Takashi
    Matsuzawa, Yoko
    Saito, Jun
    Omura, Masao
    Nishikawa, Tetsuo
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2675 - 2679
  • [3] A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
    Lukes, Andrea
    Migoya, Elizabeth
    Johnson, Brendan
    Lee, Tien-Yi
    Li, Yulan
    Ferreira, Juan Camilo Arjona
    CLINICAL PHARMACOKINETICS, 2023, 62 (08) : 1169 - 1182
  • [4] A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
    Andrea Lukes
    Elizabeth Migoya
    Brendan Johnson
    Tien-Yi Lee
    Yulan Li
    Juan Camilo Arjona Ferreira
    Clinical Pharmacokinetics, 2023, 62 : 1169 - 1182
  • [5] Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open-label, non-randomized pilot study
    Cannarella, Rossella
    Condorelli, Rosita A.
    Leanza, Claudia
    Garofalo, Vincenzo
    Aversa, Antonio
    Papa, Giuseppe
    Calogero, Aldo E.
    La Vignera, Sandro
    DIABETIC MEDICINE, 2024, 41 (01)
  • [6] Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
    Kaku, Kohei
    Maegawa, Hiroshi
    Tanizawa, Yukio
    Kiyosue, Arihiro
    Ide, Yumiko
    Tokudome, Takuto
    Hoshino, Yuji
    Yang, Jisin
    Langkilde, Anna Maria
    DIABETES THERAPY, 2014, 5 (02) : 415 - 433
  • [7] Effects of Sitagliptin versus Empagliflozin on the Stress Hyperglycemic Ratio in People with Type 2 Diabetes: An Open-Label, Randomized Controlled Trial
    Al-Nimer, Marwan S.
    Latif, Ismail Ibrahim
    Jawad, Thaqeef Murtada
    CLINICAL DIABETOLOGY, 2024, 13 (03): : 156 - 163
  • [8] Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
    Kohei Kaku
    Hiroshi Maegawa
    Yukio Tanizawa
    Arihiro Kiyosue
    Yumiko Ide
    Takuto Tokudome
    Yuji Hoshino
    Jisin Yang
    Anna Maria Langkilde
    Diabetes Therapy, 2014, 5 : 415 - 433
  • [9] 'Vidangadi Lauha' for obese type 2 diabetes mellitus patients - An open-label randomized controlled clinical trial
    Khobarkar, Punam
    Gulhane, Jayant
    Nakanekar, Amit
    JOURNAL OF AYURVEDA AND INTEGRATIVE MEDICINE, 2024, 15 (01)
  • [10] Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study
    Sun, Rui
    Yuan, Lu
    Shen, Yun
    Shen, Ziyang
    Ding, Bo
    Ma, Jianhua
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 2911 - 2919
12345